

**Speculative**  
Refer to key risks on page 4 and Biotechnology Risk Warning on page 7. Speculative securities may not be suitable for retail

**Analyst**  
John Hester 612 8224 2871

## Osprey Medical

**Authorisation**  
TS Lim 612 8224 2810

### Strong Momentum Into 2017

#### Recommendation

**Buy** (unchanged)

Price

**\$0.44**

Valuation

**\$0.55** (previously \$0.53)

Risk

**Speculative**

#### GICS Sector

Healthcare Equipment and Services

#### Expected Return

Capital growth	<b>25.0%</b>
Dividend yield	<b>0.0%</b>
Total expected return	<b>25.0%</b>


#### Company Data & Ratios

Enterprise value	<b>\$89.4m</b>
Market cap	<b>\$113.4m</b>
Issued capital	<b>257.7m</b>
Free float	<b>100%</b>
Avg. daily val. (52wk)	<b>\$59,000</b>
12 month price range	<b>\$0.19 - \$0.51</b>

#### Price Performance

	(1m)	(3m)	(12m)
Price (A\$)	0.46	0.43	0.26
Absolute (%)	-4.35	2.33	69.23
Rel market (%)	-3.27	-2.33	55.59

#### Absolute Price



SOURCE: IRESS

#### Key Points from December Quarterly Update

The company achieved 43% unit sales growth across all territories for the quarter. Unit sales in the pilot sales territory of San Antonio continue to expand and there are now 15 sales reps in the field in the US, up from 9 at the end of September.

San Antonio achieved its maiden quarter of profitability following two years of market development. Unit sales in the territory exceed the breakeven point of 75 units per month for the first time.

Also during the December quarter, the number of hospital buyers expanded by 22% to 45. There is a pipeline of 40 additional hospitals across the new sales territories currently evaluating the Dyvert system.

The company does not anticipate any material impact from the change of Government in the US. While it appears the Affordable Care Act (Obama Care) will be rolled back, the reimbursement stick imposed by Medicare and private payers on hospitals with below average care ratings will continue. This is a major positive for the company as adoption rates continue to increase as hospital operators seek methods to minimise poor patient outcomes.

#### Maintain Buy Rating

There are no significant changes to our earnings forecast. Valuation is amended from \$0.53 to \$0.55 due to small changes in the DCF model. We maintain our Buy rating. The number of hospitals using DyeVert continues to expand each quarter and it is reasonable to expect this will continue to grow. We conclude that the execution of the sales plan continues to progress well.

#### Earnings Forecast

December Year End US\$m	FY15	FY16e	FY17e	FY18e
Revenues	0.2	0.6	4.2	13.3
EBITDA \$m	-12.2	-11.0	-10.3	-4.9
NPAT (underlying) \$m	-12.2	-10.6	-9.9	-4.5
NPAT (reported) \$m	-12.2	-10.6	-9.9	-4.5
EPS underlying (cps)	-8.3	-4.9	-3.9	-1.7
EPS growth %	19%	-42%	-20%	-55%
PER (x)	-5.3	-9.1	-11.4	-25.2
FCF yield (%)	-17%	-9%	-9%	-4%
EV/EBITDA (x)	-7.3	-8.1	-8.6	-18.3
Dividend (cps)	-	-	-	-
Franking	0%	0%	0%	0%
Yield %	0.0%	0.0%	0.0%	0.0%
ROE %	0.0%	-50.4%	-86.7%	-66.0%

SOURCE: BELL POTTER SECURITIES ESTIMATES

# Hospital Buyers Grow by 22%

## Summary Financial Results – 4Q16

The key points from the 4Q16 cash flow statement and sales commentary were as follows:

- Units sales growth of 43% vs 3Q16. The company sold 636 DyeVert units in the quarter relative to 446 in prior quarter. 2H16 unit sales grew by 86%.
- We continue to expect exponential revenue growth in FY17 driven by the expanded sales force now in place. Excluding the pilot sales territory of San Antonio, units sales in other 14 territories were 400 units in total or an average of 28 units per territory for the quarter. This equates to less than 10 units per month per territory.
- Conversely, the single sales rep in the San Antonio sold 236 units or the quarter or 79 units per month.

Our forecast for FY17 stands at 12,000 units which we derive from a bottom up methodology. The key assumptions are:

- An average of 20 reps in the field across the US. Currently there are 15 reps with the company on track to expand to 20 reps by the end of 1Q17.
- An average of 50 units per rep per month at US\$350 per unit. The average of 50 units is across the year and we expect the result will be heavily skewed to 2H17.

We believe the path to profitability for the 19 new reps will be significantly ahead of the pilot market in San Antonio for the key reason that Dyvert is now second generation and there is significant clinical evidence supporting its use relative to when launched in San Antonio.

**Figure 1 - Quarterly Unit Sales and Samples**



SOURCE: COMPANY DATA

**Figure 2 – Quarterly Unit Sales History**

	Q116	Q216	Q316	Q416	Total
Unit sales	245	334	446	636	1,661
Revenues US\$'000	87	119	156	223	585
Average selling price US\$	355	356	349	351	352
Purchasing hospitals		29	39	45	
Average per hospital		12	11	14	

SOURCE: COMPANY DATA

- Free samples are provided to new hospitals trialling the product. The volume of samples issued in the quarter continues to be a strong proxy for the subsequent unit sales growth. 40 new hospitals (across all territories) are in the evaluation to purchase cycle. This is the same number of hospitals as reported in the previous quarter, however, there is a 25% churn in this statistic. Historically 85% of hospitals who sample the product become customers.
- 45 hospitals acquired product in 4Q16 – up from 39 in the previous quarter. Average unit sales per hospital is increasing which implies traction levels are improving – consistent with the experience in San Antonio.

OSP achieved 1,661 unit sales for the year which was below our target of 1,800, nevertheless the momentum going into calendar 2017 is accelerating.

- Cash receipts from customers were US\$510K for the year. The company will report total revenues of US\$585K for FY16.
- The cash outflow from operating expenses in the quarter was US\$2.7m which equates to an annualised rate of US\$10.8m. In FY17 we have allowed for A\$13.7m in operating expenses. The FY17 estimate for operating expenses may need to increase modestly, however we await the full year result before considering any amendment to earnings.
- Closing cash was US\$21.8m. The net cash burn for the quarter was US\$2.6m.

#### **DYEVERT PLUS**

DyeVert Plus is the latest release product from the company. Its key value add is real time monitoring against a pre-set limit for dye use. The FDA is expected to grant approval in 1Q17.

#### **Valuation and Recommendation**

There are no significant changes to earnings forecasts. Valuation is amended from \$0.53 to \$0.55 and we retain our Buy recommendation.

The valuation continues to be based on a Discounted Cash Flow model.

# Key Risk Areas

The clinical trial(s) which led to the approval of the first generation AVERT system and subsequent additions are now completed. Although these trials were ultimately not able to prove a reduction in CIN events, the claims for use of the product remain strong.

## **Market Adoption Risk**

To achieve the sales revenue objectives, patients, physicians, hospitals and payers must accept the company's products, specifically the DyeVert™ system, for routine use. Regulatory approvals of the company's products, including US FDA approval, does not guarantee market adoption. Acceptance of the company's products in Europe and the US will be dependent on numerous factors, including but not necessarily limited to, market perception of the risk of CIN, risk benefit and cost-benefit analysis of the use of the company's products and reimbursement.

## **Technical Risk**

The reasons for CIN are not fully understood by the medical community and are potentially multi-factorial and variable for each patient based on their health history and disease state. Given this patient variability there is no guarantee that minimising the amount of dye used will reduce the incidence of CIN.

## **Intellectual Property Risk**

The company relies on its ability to obtain and maintain patent protection of products such as the DyeVert™ System. The company's patent portfolio comprises 8 issued US patents, 15 pending US patents, and 10 international patents. There are also National Stage Applications in the EU, Japan and Australia.

## **Manufacturing and Product Quality Risk**

Osprey' products must also meet the regulatory requirements which are subject to continual review including inspections by regulatory authorities including the US FDA. Failure by the company or its suppliers to continuously comply with applicable regulatory requirements or failure to take satisfactory corrective action in response to adverse inspection, could result in enforcement actions, including a public warning letter, a shutdown of, or restrictions on, its manufacturing operations, delays in approving or clearing products, refusal to permit the import or export of its products or other enforcement action.

# About Osprey Medical

Osprey Medical is a US based company focused on the development and commercialisation of its proprietary DyeVert System. DyeVert aims to reduce the level of contrast used in certain diagnostic procedures involving the heart. Contrast Induced Nephropathy (CIN) is a serious medical condition related to kidney failure and is a side effect following use of contrast (dye) in angioplasty/cardiac stenting procedures.

Approximately 25% of patients undergoing angioplasty or cardiac stenting are at high risk of a CIN event due to their pre-existing kidney disease.

It is estimated there are up to 1.6m procedures (amongst high risk patients) conducted in the US each year that may benefit from the use of this technology. The DyeVert system has multiple measures aimed at minimising the volume of dye used, which should help reduce the number of CIN events in at risk patients.

Extensive clinical trials have now been completed in Australia, Europe and the US resulting in regulatory approvals in each of these jurisdictions.

In the US Osprey has its own dedicated sales force and does not use distributors and neither does the sales force sell any other products. It commenced marketing of the predecessor to DyeVert in 2014 with a single sales rep in Texas. Since then, it has consistently grown units sold and sampled. We expect this trend will continue as the company intends to expand the number of sales reps. In addition the company has added clinical specialists to assist the interventional cardiologist and nursing staff in their initial use of the system and training as required.

The conversion rate of hospitals upgrading from DyeVert samples to initial product orders remains high at approximately 85%. As the volume of samples expands, it is logical to assume commercial orders will follow.

There are four key drivers for physicians and hospitals to adopt the technology:

- Clinical trials proved there is up to 46% reduction in dye usage when the system is used as compared to when not used. The saving is highest in patients requiring multiple stents. Key opinion leaders in the US consistently advocate using less dye in order to reduce the risk of CIN events;
- Sub group analysis from the Avert trial showed a 49.5% reduction in the rate of CIN events in patients with grade 3 chronic kidney disease;
- Patients suffering a CIN event normally require additional hospitalisation for up to four days at a cost of up to \$10K per day to hospitals with little or no incremental payer reimbursement; and
- Medicare/Medicaid payments to hospitals are at risk if the rate of unplanned readmission for Medicare patients exceeds the national average. Targeted re-admission includes heart failure and heart attack. Any patient admitted with chest pain is likely to meet this criteria. The penalties are severe and include a 3% revenue penalty on ALL Medicare payments to the effected hospital.

The company has invested approximately US\$50m in the development of the technology to this point where it is now approved in major markets and generating revenues in the US. The company expects to commence a roll out in Europe in 2018. We expect the company will become breakeven by FY19 when revenues are expected to exceed US\$20m.

Table 1 - Financial summary

Profit & Loss (US\$m)						Valuation Ratios (US\$m)					
	FY15	FY16e	FY17e	FY18e	FY19e		FY15	FY16e	FY17e	FY18e	FY19e
<b>Year Ending December</b>						Reported EPS (cps)	-8.3	-4.9	-3.9	-1.7	1.8
Device unit sales	430	1,661	12,000	39,000	84,000	Normalised EPS (cps)	-8.3	-4.9	-3.9	-1.7	1.8
Net revenue from product sales	0.2	0.6	4.2	13.3	27.2	EPS growth (%)	19%	-42%	-20%	-55%	na
<b>COGS</b>	-0.4	-0.3	-0.8	-2.7	-5.4	<b>PE(x)</b>	<b>-5.3</b>	<b>-9.1</b>	<b>-11.4</b>	<b>-25.2</b>	<b>24.7</b>
<b>Gross profit</b>	-0.2	0.3	3.4	10.6	21.7	<b>EV/EBITDA (x)</b>	-7.3	-8.1	-8.6	-18.3	21.4
<b>GP margin</b>	0%	50%	80%	80%	80%	<b>EV/EBIT (x)</b>	-7.3	-8.1	-8.6	-17.9	21.9
R&D incentive/Upfront receipts	-	-	-	-	-	NTA (cps)	7.4	8.5	4.6	2.9	4.7
<b>Total revenues</b>	<b>0.2</b>	<b>0.6</b>	<b>4.2</b>	<b>13.3</b>	<b>27.2</b>	P/NTA (x)	5.9	5.2	9.5	15.2	9.4
<b>Other expenses</b>	<b>-12.0</b>	<b>-11.3</b>	<b>-13.7</b>	<b>-15.5</b>	<b>-17.6</b>	Book Value (cps)	7.5	8.6	4.7	2.9	4.7
<b>EBITDA</b>	<b>-12.2</b>	<b>-11.0</b>	<b>-10.3</b>	<b>-4.9</b>	<b>4.2</b>	Price/Book (x)	5.9	5.1	9.4	15.0	9.3
D&A	0.0	-0.1	-0.1	-0.1	-0.1	DPS (cps)	-	-	-	-	-
<b>EBIT</b>	<b>-12.2</b>	<b>-11.1</b>	<b>-10.4</b>	<b>-5.0</b>	<b>4.1</b>	Payout ratio %	0%	0%	0%	0%	0%
Sundry income	0.1	0.5	0.5	0.5	0.5	Dividend Yield %	0.0%	0.0%	0.0%	0.0%	0.0%
Pre tax profit	-12.2	-10.6	-9.9	-4.5	4.6	Franking %	170%	0%	0%	0%	0%
Tax expense	-	-	-	-	-	FCF yield %	-17%	-9%	-9%	-4%	4%
<b>NPAT - normalised</b>	<b>-12.2</b>	<b>-10.6</b>	<b>-9.9</b>	<b>-4.5</b>	<b>4.6</b>	Net debt/Equity	0%	0%	0%	0%	0%
Net abnormal items	-	-	-	-	-	Net debt/Assets	0%	0%	0%	0%	0%
<b>Reported NPAT</b>	<b>-12.2</b>	<b>-10.6</b>	<b>-9.9</b>	<b>-4.5</b>	<b>4.6</b>	Gearing	0%	net cash	net cash	net cash	net cash
<b>Cashflow (US\$m)</b>						Net debt/EBITDA (x)	n/a	n/a	n/a	n/a	n/a
	FY15	FY16e	FY17e	FY18e	FY19e	Interest cover (x)	n/a	n/a	n/a	n/a	n/a
Gross cashflow	-11.6	-11.0	-10.8	-4.9	4.7	<b>Unit sales</b>					
Net interest	0.3	0.5	0.5	0.5	0.5		FY16e	FY17e	FY18e	FY19e	
Tax paid	0.0	0.0	0.0	0.0	0.0	Europe	-	-	3,000	18,000	
<b>Operating cash flow</b>	<b>-11.4</b>	<b>-10.5</b>	<b>-10.3</b>	<b>-4.4</b>	<b>5.2</b>	USA	1,800	12,000	36,000	66,000	
Maintenance capex	-0.1	-0.2	-0.2	-0.2	-0.2	Australia/Asia Pacific	-	-	-	-	
Capitalised clinical trial spend	0.0	0.0	0.0	0.0	0.0	<b>Total unit sales</b>	<b>1,800</b>	<b>12,000</b>	<b>39,000</b>	<b>84,000</b>	
<b>Free cash flow</b>	<b>-11.5</b>	<b>-10.7</b>	<b>-10.5</b>	<b>-4.6</b>	<b>5.0</b>	Average revenue per sale A\$'000	-	350	340	323	
Business acquisitions	0.0	0.0	0.0	0.0	0.0	<b>Half Year Earnings Split</b>					
Proceeds from issuance	11.9	21.0	0.0	0.0	0.0		1H16	2H16e			
Movement in investments	0.0	0.0	0.0	0.0	0.0	Unit sales	590	1,071			
Dividends paid	0.0	0.0	0.0	0.0	0.0	Revenues	0.2	0.4			
<b>Change in cash held</b>	<b>0.4</b>	<b>10.3</b>	<b>(10.5)</b>	<b>(4.6)</b>	<b>5.0</b>	EBIT	-6.1	-5.0			
Cash at beginning of period	11.3	11.8	22.0	11.6	7.0	NPAT	-6.1	-4.5			
<b>Cash at year end</b>	<b>11.8</b>	<b>22.0</b>	<b>11.6</b>	<b>7.0</b>	<b>12.0</b>						
<b>Balance Sheet (US\$m)</b>											
Cash	11.8	22.0	11.6	7.0	12.0						
Receivables	-	0.1	0.5	1.7	3.4						
Short term investments	0.3	0.3	0.3	0.3	0.4						
Other current assets	0.1	0.1	0.1	0.1	0.1						
Property, Plant and Equipment	0.3	0.4	0.5	0.6	0.7						
Intangible assets	0.1	0.1	0.1	0.1	0.1						
<b>Total assets</b>	<b>12.6</b>	<b>23.0</b>	<b>13.1</b>	<b>9.8</b>	<b>16.7</b>						
Trade payables /accruals	1.0	1.0	1.1	2.2	4.5						
Other liabilities	-	-	-	-	-						
Debt - interest bearing debt	-	-	-	-	-						
<b>Total Liabilities</b>	<b>1.0</b>	<b>1.0</b>	<b>1.1</b>	<b>2.2</b>	<b>4.5</b>						
<b>Net Assets</b>	<b>11.6</b>	<b>22.0</b>	<b>12.0</b>	<b>7.6</b>	<b>12.1</b>						
Share capital	64.8	85.8	85.8	85.8	85.8						
Retained earnings	(53.2)	(63.8)	(73.8)	(78.2)	(73.7)						
Reserves	-	-	-	-	-						
<b>Shareholders Equity</b>	<b>11.6</b>	<b>22.0</b>	<b>12.0</b>	<b>7.6</b>	<b>12.1</b>						

SOURCE: BELL POTTER SECURITIES ESTIMATES

**Recommendation structure**

**Buy:** Expect >15% total return on a 12 month view. For stocks regarded as 'Speculative' a return of >30% is expected.

**Hold:** Expect total return between -5% and 15% on a 12 month view

**Sell:** Expect <-5% total return on a 12 month view

*Speculative Investments are either start-up enterprises with nil or only prospective operations or recently commenced operations with only forecast cash flows, or companies that have commenced operations or have been in operation for some time but have only forecast cash flows and/or a stressed balance sheet.*

*Such investments may carry an exceptionally high level of capital risk and volatility of returns.*

**Research Team**

Staff Member	Title/Sector	Phone	@bellpotter.com.au
TS Lim	Head of Research	612 8224 2810	tslim
<b>Industrials</b>			
Sam Haddad	Industrials	612 8224 2819	shaddad
Jonathon Higgins	Industrials	613 9235 8706	jhiggins
John O'Shea	Industrials	613 9235 1633	joshea
Chris Savage	Industrials	612 8224 2835	csavage
Jonathan Snape	Industrials	613 9235 1601	jsnape
Tim Piper	Industrials	612 8224 2825	tpiper
John Hester	Healthcare	612 8224 2871	jhester
Tanushree Jain	Healthcare/Biotech	612 8224 2849	tnjain
<b>Financials</b>			
TS Lim	Banks/Regionals	612 8224 2810	tslim
Lafitani Sotiriou	Diversified	613 9235 1668	Isotiriou
<b>Resources</b>			
Peter Arden	Resources	613 9235 1833	parden
David Coates	Resources	612 8224 2887	dcoates
<b>Associates</b>			
James Filius	Associate Analyst	613 9235 1612	jfilius

**Bell Potter Securities Limited**

ACN 25 006 390 7721

Level 38, Aurora Place  
88 Phillip Street, Sydney 2000

Telephone +61 2 9255 7200

www.bellpotter.com.au

**The following may affect your legal rights. Important Disclaimer:**

This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of Bell Potter Securities Limited. In the USA and the UK this research is only for institutional investors. It is not for release, publication or distribution in whole or in part to any persons in the two specified countries. In Hong Kong this research is being distributed by Bell Potter Securities (HK) Limited which is licensed and regulated by the Securities and Futures Commission, Hong Kong. This is general investment advice only and does not constitute personal advice to any person. Because this document has been prepared without consideration of any specific client's financial situation, particular needs and investment objectives ('relevant personal circumstances'), a Bell Potter Securities Limited investment adviser (or the financial services licensee, or the representative of such licensee, who has provided you with this report by arrangement with Bell Potter Securities Limited) should be made aware of your relevant personal circumstances and consulted before any investment decision is made on the basis of this document. While this document is based on information from sources which are considered reliable, Bell Potter Securities Limited has not verified independently the information contained in the document and Bell Potter Securities Limited and its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does Bell Potter Securities Limited accept any responsibility for updating any advice, views opinions, or recommendations contained in this document or for correcting any error or omission which may become apparent after the document has been issued. Except insofar as liability under any statute cannot be excluded. Bell Potter Limited and its directors, employees and consultants do not accept any liability (whether arising in contract, in tort or negligence or otherwise) for any error or omission in this document or for any resulting loss or damage (whether direct, indirect, consequential or otherwise) suffered by the recipient of this document or any other person.

**Disclosure of interest:**

Bell Potter Securities Limited, its employees, consultants and its associates within the meaning of Chapter 7 of the Corporations Law may receive commissions, underwriting and management fees from transactions involving securities referred to in this document (which its representatives may directly share) and may from time to time hold interests in the securities referred to in this document.

Disclosure: Bell Potter Securities acted as Lead manager of the 2016 Capital Raising and received fees for that service.

**Biotechnology Risk Warning:**

The stocks of biotechnology companies without revenue streams from product sales or ongoing service revenue should always be regarded as speculative in character. Since most biotechnology companies fit this description, the speculative designation also applies to the entire sector. The fact that the intellectual property base of a typical biotechnology company lies in science and not generally regarded as accessible to the layman adds further to the riskiness with which biotechnology investments ought to be regarded. Stocks with 'Speculative' designation are prone to high volatility in share price movements. Clinical and regulatory risks are inherent in biotechnology stocks. Biotechnology developers usually seek US FDA approval for their technology which is a long and arduous three phase process to prove the safety, effectiveness and appropriate application or use of the developed drug, and even after approval a drug can be the subject of an FDA investigation of subsequently discovered possible links between the drug and other un-previously diagnosed diseases. Investors are advised to be cognisant of these risks before buying such a stock including **Osprey Medical** (of which a list of specific risks is highlighted within).

**ANALYST CERTIFICATION:**

Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.